BRPI0511543A - ácido 4-hidróxi-4-metila-piperidina-1-carboxìlico 4-metóxi-7-morfolin-4-il-benzotiazol-2-il)-amida - Google Patents
ácido 4-hidróxi-4-metila-piperidina-1-carboxìlico 4-metóxi-7-morfolin-4-il-benzotiazol-2-il)-amidaInfo
- Publication number
- BRPI0511543A BRPI0511543A BRPI0511543-4A BRPI0511543A BRPI0511543A BR PI0511543 A BRPI0511543 A BR PI0511543A BR PI0511543 A BRPI0511543 A BR PI0511543A BR PI0511543 A BRPI0511543 A BR PI0511543A
- Authority
- BR
- Brazil
- Prior art keywords
- methoxy
- amide
- hydroxy
- methyl
- carboxylic acid
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- VCEGDBURKQJDAX-UHFFFAOYSA-N 4-hydroxy-4-methylpiperidine-1-carboxylic acid Chemical compound CC1(O)CCN(C(O)=O)CC1 VCEGDBURKQJDAX-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- XNBRWUQWSKXMPW-UHFFFAOYSA-N Tozadenant Chemical compound C1=2SC(NC(=O)N3CCC(C)(O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 XNBRWUQWSKXMPW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- -1 opioids Chemical compound 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
áCIDO 4-HIDRõXI-4-METILA-PIPERIDINA-1-CARBOXILICO (4-METõXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-AMIDA. A presente invenção refere-se ao composto da fórmula que é ácido 4-hidróxi-4-metila-piperidina-1 -carboxílico (4-metóxi-7-morfolin-4-iI-benzotiazol-2-iI)-amida, e seus sais de adição ácidos farmaceuticamente aceitáveis. Foi descoberto que o composto é útil para o tratamento ou prevenção de doença de Alzheimer, doença de Parkinson, doença de Huntington, neuroproteção, esquizofrenia, ansiedade, dor, déficit de respiração, depressão, ADHD (distúrbio de déficit de atenção, hiperatividade), dependência a anfetaminas, cocaína, opióides, etanol, nicotina, canabinóides, ou para o tratamento de asma, respostas alérgicas, hipoxia, isquemia, derrame e abuso de substâncias, ou para uso como relaxante muscular, agentes antipsicóticos, antiepilépticos, anticonvulsivos e cardioprotetores.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102262.5 | 2004-05-24 | ||
| EP04102262 | 2004-05-24 | ||
| PCT/EP2005/005329 WO2005116026A1 (en) | 2004-05-24 | 2005-05-17 | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0511543A true BRPI0511543A (pt) | 2008-01-02 |
| BRPI0511543B1 BRPI0511543B1 (pt) | 2022-05-10 |
Family
ID=34967309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511543-4A BRPI0511543B1 (pt) | 2004-05-24 | 2005-05-17 | Ácido 4-hidróxi-4-metila-piperidina-1-carboxílico (4-metóxi-7-morfolin-4-il-benzotiazol-2-il)- amida, seu processo de preparação, uso e medicamento que o compreende |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US7368446B2 (pt) |
| EP (1) | EP1753760B1 (pt) |
| JP (1) | JP4668265B2 (pt) |
| CN (1) | CN1956983B (pt) |
| AR (1) | AR048973A1 (pt) |
| AT (1) | ATE382619T1 (pt) |
| AU (1) | AU2005247567B2 (pt) |
| BR (1) | BRPI0511543B1 (pt) |
| CA (1) | CA2567703C (pt) |
| CR (1) | CR8703A (pt) |
| CY (1) | CY1108104T1 (pt) |
| DE (1) | DE602005004142T2 (pt) |
| DK (1) | DK1753760T3 (pt) |
| DO (1) | DOP2005000091A (pt) |
| EA (1) | EA011279B1 (pt) |
| EC (1) | ECSP067018A (pt) |
| ES (1) | ES2297710T3 (pt) |
| GT (1) | GT200500124A (pt) |
| HK (1) | HK1105199A1 (pt) |
| HN (1) | HN2005000238A (pt) |
| HR (1) | HRP20080027T3 (pt) |
| IL (1) | IL179364A (pt) |
| MA (1) | MA28601B1 (pt) |
| MX (1) | MXPA06013417A (pt) |
| MY (1) | MY140011A (pt) |
| NO (1) | NO336939B1 (pt) |
| NZ (1) | NZ550763A (pt) |
| PA (1) | PA8633901A1 (pt) |
| PE (1) | PE20060274A1 (pt) |
| PL (1) | PL1753760T3 (pt) |
| PT (1) | PT1753760E (pt) |
| RS (1) | RS50574B (pt) |
| SI (1) | SI1753760T1 (pt) |
| SV (1) | SV2006002125A (pt) |
| TN (1) | TNSN06371A1 (pt) |
| TW (1) | TWI358297B (pt) |
| UA (1) | UA87142C2 (pt) |
| WO (1) | WO2005116026A1 (pt) |
| ZA (1) | ZA200609136B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ATE359075T1 (de) * | 2002-12-20 | 2007-05-15 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| EP1998748B1 (en) | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
| BRPI0814672A2 (pt) * | 2007-07-23 | 2014-09-30 | Synosia Therapeutics | Método de tratamento de um paciente, e de distúrbio de estresse pós-traumático, e, métodos para melhorar a resiliência em um paciente e para diagnosticar distúrbio de estresse pós-traumático em um paciente. |
| RS53941B1 (en) | 2009-01-12 | 2015-08-31 | Pfizer Limited | SULFONAMID DERIVATIVES |
| US8168785B2 (en) | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| CA2804173C (en) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| AU2013251079B2 (en) * | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| WO2018059531A1 (zh) * | 2016-09-30 | 2018-04-05 | 苏州晶云药物科技有限公司 | 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途 |
| US11453647B2 (en) * | 2017-08-21 | 2022-09-27 | Merck Patent Gmbh | Benzimidazole derivatives as adenosine receptor antagonists |
| KR20200043434A (ko) | 2017-08-21 | 2020-04-27 | 메르크 파텐트 게엠베하 | 아데노신 수용체 길항제로서의 퀴녹살린 유도체 |
| WO2019141096A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 取代脲类化合物及其制备方法和用途 |
| US20220088024A1 (en) | 2018-12-20 | 2022-03-24 | Biotie Therapies, Inc. | Methods for treating cancer using tozadenant |
| DE102019110904B4 (de) | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH505543A (de) * | 1968-11-01 | 1971-04-15 | Ciba Geigy Ag | Schädlingsbekämpfungsmittel |
| NL7109150A (pt) | 1970-07-06 | 1972-01-10 | ||
| US4028374A (en) * | 1975-11-03 | 1977-06-07 | Morton-Norwich Products, Inc. | Antibacterial thiocyanatobenzothiazoles |
| DE2656468A1 (de) | 1976-12-14 | 1978-06-15 | Boehringer Mannheim Gmbh | N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung |
| KR930005004B1 (ko) | 1985-04-15 | 1993-06-11 | 쟈안센 파아마슈우티카 엔. 부이. | 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법 |
| FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| IL90337A0 (en) | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
| WO1990015801A1 (en) | 1989-06-22 | 1990-12-27 | Pfizer Inc. | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases |
| EP0427963B1 (de) * | 1989-11-10 | 1994-03-30 | Agrolinz Agrarchemikalien Gesellschaft M.B.H. | Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe |
| ATE188704T1 (de) | 1992-05-21 | 2000-01-15 | Otsuka Pharma Co Ltd | Phosphonsäurediester-derivat |
| FR2753970B1 (fr) | 1996-10-01 | 1998-10-30 | Synthelabo | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique |
| JPH11130761A (ja) | 1997-10-24 | 1999-05-18 | Otsuka Pharmaceut Co Ltd | ベンゾチアゾール誘導体 |
| KR20010031912A (ko) | 1997-11-10 | 2001-04-16 | 스티븐 비. 데이비스 | 벤조티아졸 단백질 티로신 키나제 억제제 |
| BR9907183A (pt) | 1998-01-23 | 2003-06-10 | Versicor Inc | Colet neas combinatórias de oxazolidinona, composições e processos de preparação |
| EP1117663A2 (en) | 1998-09-30 | 2001-07-25 | Neurogen Corporation | 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| DE60023949T2 (de) | 2000-05-12 | 2006-08-10 | Corning Inc. | Verfahren zum herstellen einer vorform mit schutzumhüllung für optische fasern |
| AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
-
2005
- 2005-05-17 NZ NZ550763A patent/NZ550763A/en not_active IP Right Cessation
- 2005-05-17 PL PL05741185T patent/PL1753760T3/pl unknown
- 2005-05-17 DK DK05741185T patent/DK1753760T3/da active
- 2005-05-17 AU AU2005247567A patent/AU2005247567B2/en active Active
- 2005-05-17 CA CA2567703A patent/CA2567703C/en active Active
- 2005-05-17 JP JP2007513750A patent/JP4668265B2/ja not_active Expired - Fee Related
- 2005-05-17 RS RSP-2008/0125A patent/RS50574B/sr unknown
- 2005-05-17 MX MXPA06013417A patent/MXPA06013417A/es active IP Right Grant
- 2005-05-17 SI SI200530160T patent/SI1753760T1/sl unknown
- 2005-05-17 CN CN200580016875XA patent/CN1956983B/zh not_active Expired - Fee Related
- 2005-05-17 AT AT05741185T patent/ATE382619T1/de active
- 2005-05-17 ES ES05741185T patent/ES2297710T3/es active Active
- 2005-05-17 PT PT05741185T patent/PT1753760E/pt unknown
- 2005-05-17 DE DE602005004142T patent/DE602005004142T2/de active Active
- 2005-05-17 UA UAA200613530A patent/UA87142C2/ru unknown
- 2005-05-17 EA EA200602048A patent/EA011279B1/ru not_active IP Right Cessation
- 2005-05-17 BR BRPI0511543-4A patent/BRPI0511543B1/pt not_active IP Right Cessation
- 2005-05-17 WO PCT/EP2005/005329 patent/WO2005116026A1/en active Application Filing
- 2005-05-17 EP EP05741185A patent/EP1753760B1/en active Active
- 2005-05-18 US US11/132,019 patent/US7368446B2/en active Active
- 2005-05-20 MY MYPI20052309A patent/MY140011A/en unknown
- 2005-05-20 DO DO2005000091A patent/DOP2005000091A/es unknown
- 2005-05-20 TW TW094116495A patent/TWI358297B/zh not_active IP Right Cessation
- 2005-05-23 AR ARP050102104A patent/AR048973A1/es not_active Application Discontinuation
- 2005-05-23 PE PE2005000569A patent/PE20060274A1/es active IP Right Grant
- 2005-05-23 PA PA20058633901A patent/PA8633901A1/es unknown
- 2005-05-23 GT GT200500124A patent/GT200500124A/es unknown
- 2005-05-23 HN HN2005000238A patent/HN2005000238A/es unknown
- 2005-05-24 SV SV2005002125A patent/SV2006002125A/es unknown
-
2006
- 2006-10-24 CR CR8703A patent/CR8703A/es unknown
- 2006-11-02 ZA ZA200609136A patent/ZA200609136B/xx unknown
- 2006-11-14 TN TNP2006000371A patent/TNSN06371A1/fr unknown
- 2006-11-16 IL IL179364A patent/IL179364A/en active IP Right Grant
- 2006-11-21 EC EC2006007018A patent/ECSP067018A/es unknown
- 2006-11-22 MA MA29481A patent/MA28601B1/fr unknown
- 2006-12-12 NO NO20065732A patent/NO336939B1/no not_active IP Right Cessation
-
2007
- 2007-09-27 HK HK07110484.5A patent/HK1105199A1/xx not_active IP Right Cessation
-
2008
- 2008-01-18 HR HR20080027T patent/HRP20080027T3/xx unknown
- 2008-02-28 CY CY20081100232T patent/CY1108104T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511543A (pt) | ácido 4-hidróxi-4-metila-piperidina-1-carboxìlico 4-metóxi-7-morfolin-4-il-benzotiazol-2-il)-amida | |
| ECSP088499A (es) | Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia | |
| BRPI0510515A (pt) | compostos de morfolina | |
| ECSP088969A (es) | Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia | |
| BR0214825A (pt) | Uréias de 2-aminobenzotiazóis como moduladores de adenosina | |
| DE602005009117D1 (de) | Verfahren zur Herstellung eines gemusterten Formkörpers | |
| BR112014010577A2 (pt) | derivados de ciclo-hexilamina tendo atividade agonista beta2 adrenérgico e antagonista muscarínico m3 | |
| MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| GEP20094640B (en) | Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| BRPI0815324A2 (pt) | "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos" | |
| UY30414A1 (es) | Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| IL194947A0 (en) | Aryl-4-ethynyl-isoxazole derivatives | |
| BRPI0515486A (pt) | composição de agentes de revestimento estável à hidrólise | |
| MY147404A (en) | Process for preparation of n-benzoyl-staurosporine | |
| MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
| SG140605A1 (en) | Benzothiazole derivatives | |
| BRPI0509382A (pt) | processo para a preparação de um sal monocloridrato de composto, monocloridrato cristalino, processo para obter monocloridrato cristalino, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, uso de monocloridrato cristalino, formulação farmacêutica, e, combinação | |
| IL184849A0 (en) | Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation | |
| BRPI0506490A (pt) | compostos orgánicos | |
| TW200608970A (en) | Substituted benzothiazoles | |
| BR0213907A (pt) | Derivados de heteroarila como ligandos superiores para receptor de nociceptina orl-1 | |
| DE602007010445D1 (de) | Verfahren zur synthese von (+) und (-)-1-aryl-3-azabicycloä3.1.0ühexanen | |
| BRPI0912537A2 (pt) | composto, uso de um composto, composição farmacêutica, métodos para as terapias de dor, do mal de alzheimer, de esquizofrenia, de ansiedade, de depressão em um animal de sangue quente, e, processo para preparar um composto. | |
| AR063924A1 (es) | Analogos de pirazol | |
| CL2007003275A1 (es) | Compuestos derivados de 4-imidazoles sustituidos; proceso de preparacion; medicamento; y uso para el tratamiento de depresion, trastornos de ansiedad, trastornos psicoticos, esquizofrenia, enfermedad de parkinson, migrana, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |